Study finds race has an impact on both enrollment and disenrollment in hospice care

June 25, 2012

INDIANAPOLIS -- Although use of hospice services is increasing dramatically, a study led by Regenstrief Institute investigator Kathleen T. Unroe, M.D., MHA, an assistant research professor of medicine at the Indiana University School of Medicine, has found that nonwhite Medicare patients with heart failure are 20 percent less likely to enroll in hospice than their white counterparts.

The study also found that racial differences in hospice use persisted over time and that nonwhite patients who do enroll in hospice are more likely to disenroll than white patients.

These findings are reported in "Racial Differences in Hospice Use and Patterns of Care after Enrollment in Hospice among Medicare Beneficiaries with Heart Failure" published in the June issue of American Heart Journal.

Significantly, among those who elected for hospice care, nonwhite patients were more likely to have an emergency department visit, to be hospitalized and to have an intensive care unit stay. Among patients who remained in hospice until death, nonwhite patients had higher rates of acute care resource use and higher overall costs than white patients in hospice.

"When considering end-of-life care options, it is important to consider hospice services at home, in nursing homes or in hospice facilities," said Dr. Unroe, a center scientist with the IU Center for Aging Research. "Our findings highlight that there is a significant difference between how white patients and nonwhite patients and their families utilize hospice services."

The researchers studied a national sample of 219,275 Medicare beneficiaries with heart failure.

According to the National Hospice and Palliative Care Organization, about 1.58 million patients received hospice services in 2010. About 42 percent of all deaths in the United States were under the care of a hospice program in 2010. Heart disease was the third most common diagnosis of individuals receiving hospice care.

An individual is eligible for hospice care if a physician estimates a life expectancy of six months or less, should the disease run its normal course. The emphasis of hospice is on enhancing the quality of life until death.

Co-authors of the study in addition to Dr. Unroe, who conducted the work while a geriatric medicine fellow at Duke University, are Melissa A. Greiner, M.S., Kimberly S. Johnson, M.D., MHS, Lesley H. Curtis, Ph.D., and Soko Setoguchi, M.D., Dr.P.H., of Duke. The research was supported by a John A. Hartford Foundation award to Dr. Unroe.

In a previous study of Medicare patients who died of heart failure, Dr. Unroe and colleagues found that use of hospice among heart failure patients "dramatically" increased, from 19 percent in 2000 to nearly 40 percent in 2007. However, rates of hospitalization in the final six months of life remained constant at about 80 percent.
-end-


Indiana University School of Medicine

Related Heart Failure Articles from Brightsurf:

Top Science Tip Sheet on heart failure, heart muscle cells, heart attack and atrial fibrillation results
Newly discovered pathway may have potential for treating heart failure - New research model helps predict heart muscle cells' impact on heart function after injury - New mass spectrometry approach generates libraries of glycans in human heart tissue - Understanding heart damage after heart attack and treatment may provide clues for prevention - Understanding atrial fibrillation's effects on heart cells may help find treatments - New research may lead to therapy for heart failure caused by ICI cancer medication

Machining the heart: New predictor for helping to beat chronic heart failure
Researchers from Kanazawa University have used machine learning to predict which classes of chronic heart failure patients are most likely to experience heart failure death, and which are most likely to develop an arrhythmic death or sudden cardiac death.

Heart attacks, heart failure, stroke: COVID-19's dangerous cardiovascular complications
A new guide from emergency medicine doctors details the potentially deadly cardiovascular complications COVID-19 can cause.

Autoimmunity-associated heart dilation tied to heart-failure risk in type 1 diabetes
In people with type 1 diabetes without known cardiovascular disease, the presence of autoantibodies against heart muscle proteins was associated with cardiac magnetic resonance (CMR) imaging evidence of increased volume of the left ventricle (the heart's main pumping chamber), increased muscle mass, and reduced pumping function (ejection fraction), features that are associated with higher risk of failure in the general population

Transcendental Meditation prevents abnormal enlargement of the heart, reduces chronic heart failure
A randomized controlled study recently published in the Hypertension issue of Ethnicity & Disease found the Transcendental Meditation (TM) technique helps prevent abnormal enlargement of the heart compared to health education (HE) controls.

Beta blocker use identified as hospitalization risk factor in 'stiff heart' heart failure
A new study links the use of beta-blockers to heart failure hospitalizations among those with the common 'stiff heart' heart failure subtype.

Type 2 diabetes may affect heart structure and increase complications and death among heart failure patients of Asian ethnicity
The combination of heart failure and Type 2 diabetes can lead to structural changes in the heart, poorer quality of life and increased risk of death, according to a multi-country study in Asia.

Preventive drug therapy may increase right-sided heart failure risk in patients who receive heart devices
Patients treated preemptively with drugs to reduce the risk of right-sided heart failure after heart device implantation may experience the opposite effect and develop heart failure and post-operative bleeding more often than patients not receiving the drugs.

How the enzyme lipoxygenase drives heart failure after heart attacks
Heart failure after a heart attack is a global epidemic leading to heart failure pathology.

Novel heart pump shows superior outcomes in advanced heart failure
Severely ill patients with advanced heart failure who received a novel heart pump -- the HeartMate 3 left ventricular assist device (LVAD) -- suffered significantly fewer strokes, pump-related blood clots and bleeding episodes after two years, compared with similar patients who received an older, more established pump, according to research presented at the American College of Cardiology's 68th Annual Scientific Session.

Read More: Heart Failure News and Heart Failure Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.